ClinicalTrials.gg
CompletedNCT00540618Updated Nov 28, 2007

A Phase II Study of MEDI-507, Administered by Injection to Adults With Psoriasis

A Phase 2 interventional study of MEDI-507 and Placebo in Plaque Psoriasis, sponsored by MedImmune LLC. Completed at 43 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2007-11-28.

Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
420
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Psoriasis by AstraZeneca — none open to participants now, none under way, none of them phase 3. Psoriasis · AstraZeneca.

Started
2001
with 1 other
Phase 2
4 of 11
none open now
Registered
5th of 11
by date

Among the 11 studies in Psoriasis by AstraZeneca, this one is one of 2 that started in 2001, is one of 4 in phase 2, and was the 5th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

None of the 11 studies in Psoriasis by AstraZeneca is open now. The open studies under Psoriasis, anywhere →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Psoriasis by AstraZeneca as a file.
02

Study summary

To compare disease activity, as measured by PASI score, of three MEDI-507 dosing (injection)regimens vs. placebo.

Read the detailed description

The primary objective of this study is to compare disease activity, as measured by PASI score, of three MEDI-507 dosing regimens (5 mg for 12 weeks, 5 mg for 6 weeks, 7 mg for 4 weeks) versus placebo administered weekly by SC injection.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Plaque psoriasis involving at least 10% of body surface area
  • Age 18 through 65 years at the time of the first dose of study drug
  • Both males and females are eligible. However, sexually active females, unless surgically sterile or at least 1 year , must have used an effective method of avoiding pregnancy (including oral or implanted , IUD, female condom, diaphragm with spermicide, cervical cap, abstinence, use of a condom by the sexual partner or sterile sexual partner) for 30 days prior to the first dose of study drug and must agree to continue
  • Currently receiving no therapy for psoriasis except emollients (certain other over-the-counter products may be allowed with prior approval of the sponsor)
  • Written obtained from the patient
  • Ability to complete follow-up period of 167 days as required by the protocol

Exclusion criteria

Exclusion Criteria:

  • Pustular, guttate, or erythrodermic psoriasis as the predominant disease type
  • PASI score \<8
  • At screening (must be within 21 days before study entry) any of the following: lymphocyte count under 1,200 cells/mm3, WBC under 4,000 cells/mm3, hematocrit below 32%, below 110,000 cells/mm3, creatinine, , ALT over 1.5 times
  • At screening (must be within 21 days before study entry) any clinical evidence of , , or active hepatitis A infection
  • Pregnancy (must have a negative serum pregnancy test within 21 days prior to the first dose of study drug, and urine pregnancy test must be negative on Study Day 0 before study entry)
  • History of cancer (except excision of basal cell carcinoma)
  • Any documented immunodeficiency
  • A history of prior administration of monoclonal antibodies or related proteins
  • Receipt of systemic retinoids, , cyclosporin A, methotrexate, phototherapy or coal tar treatment in the past 4 weeks
  • Use of topical therapy (except emollients) for psoriasis in the past 2 weeks (certain other over-the-counter products may be allowed with prior approval of the sponsor)
  • Receipt of any drug therapy within 6 weeks before the first dose of study drug in this protocol (use of licensed agents for indications not listed in the package insert is permitted)
  • Current or planned participation in a research protocol in which an investigational agent or therapy may be administered
  • Nursing mother
  • Acute illness including infections 15. Clinical manifestations of significant end organ dysfunction or failure that may compromise the safety of the volunteer in the study
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Double
Enrollment
420 participants (actual)

Study arms

  • Active comparator
    1

    MEDI-507

    Drug: MEDI-507

  • Placebo comparator
    2

    Other: Placebo

  • Active comparator
    3

    MEDI-507

    Drug: MEDI-507

  • Active comparator
    4

    MEDI-507

    Drug: MEDI-507

Interventions

  • Compare in a placebo controlled manner, the disease activity of three dosing regimens of MEDI-507 (Monoclonal Antibody)

  • OtherPlacebo
  • Monoclonal Antibody (5 mg for 12 weeks and 5 mg for 6 weeks)

  • Administered 7 mg for 4 weeks by injection (Monoclonal Antibody)

06

What researchers measure

Primary outcomes

  1. Biological activity will be assessed primarily by the Psoriasis Activity and Severity Index (PASI)

    Time frame: Days 14, 28, 42, 56, 70, 91, 107, and 167

Secondary outcomes

  1. Observe adverse and serious adverse events

    Time frame: Day 107 and 167

07

Study locations

43 sites
  • MDS Pharma Services (US) Inc.
    Phoenix, Arizona 85040, United States
  • Bressinck-Parker-Dinehart-Sangster Dermatology, PA
    Little Rock, Arkansas 72205, United States
  • Associates in Research, Inc.
    Fresno, California 93710, United States
  • nTouch Research Corporation
    San Diego, California 92103, United States
  • Solano Clinical Research
    Vallejo, California 94589, United States
  • Dermatology Specialists, Inc.
    Vista, California 92083, United States
  • Colorado Medical Research Center, Inc.
    Denver, Colorado 80210, United States
  • Cherry Creek Dermatology
    Denver, Colorado 80246, United States
  • The Savin Center, PC
    New Haven, Connecticut 06511, United States
  • North Florida Dermatology Associates, PA
    Jacksonville, Florida 32204, United States
  • ICSL-Clinical Studies
    Sarasota, Florida 34232, United States
  • Comprehensive Research Institute
    Tampa, Florida 33607, United States
  • Atlanta Dermatology, Vein & Research Center, LLC
    Alpharetta, Georgia 30005, United States
  • Northwestern University Medical School
    Chicago, Illinois 60611-2923, United States
  • Research Solutions, LLC
    Evansville, Indiana 47714, United States
  • The South Bend Clinic
    South Bend, Indiana 46617, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • FutureCare Studies
    Springfield, Massachusetts 01107, United States
  • Washington University School of Medicine
    St. Louis, Missouri 63110, United States
  • Probe Inc.
    Delran, New Jersey 08075, United States
  • University of Medicine & Dentistry of New Jersey Robert Wood Johnson Medical School and Clinical Research Center
    New Brunswick, New Jersey 08903-0019, United States
  • Associates in Dermatology Research
    Rutherford, New Jersey 07070, United States
  • Sadick Research Group
    New York, New York 10021, United States
  • Mount Sinai School of Medicine
    New York, New York 10029, United States
  • Wake Forest University School of Medicine
    Winston-Salem, North Carolina 27157, United States
  • University Dermatology Consultants, Inc.
    Cincinnatti, Ohio 45219, United States
  • Oregon Medical Research Center, PC
    Portland, Oregon 97223, United States
  • Northeast Clinical Research Center
    Allentown, Pennsylvania 18104, United States
  • Paddington Testing Company
    Philadelphia, Pennsylvania 19103, United States
  • Radiant Research
    Philadelphia, Pennsylvania 19115, United States
  • Clinicalm Partners-LLC
    Johnston, Rhode Island 02919, United States
  • Harmony Clinical Research, Inc.
    Johnson City, Tennessee 37601, United States
  • Dermatology Consultants, PC
    Nashville, Tennessee 37205, United States
  • Veteran's Administration Medical Center
    Nashville, Tennessee 37212-2637, United States
  • Breco Research, Ltd.
    Houston, Texas 77024, United States
  • Dermatology Clinical Research Center of San Antonio
    San Antonio, Texas 78229, United States
  • The Dermatology Centre
    Calgary, Alberta T2S 3B3, Canada
  • NewLab Clinical Research
    St. Johns, Newfoundland and Labrador A1B 3E1, Canada
  • Queen Elizabeth II Health Sciences Center
    Halifax, Nova Scotia B3H 1V8, Canada
  • Probity Medical Research
    Waterloo, Ontario N2J 1B7, Canada
  • Probity Medical Research
    Windsor, Ontario N8X 3V6, Canada
  • Innovaderm Research Inc.
    Montreal, Quebec H2K 4L5, Canada
  • International Dermatology Research
    Montreal, Quebec H3H 1V4, Canada
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2001 and a completion of Jul 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2007
First posted
Oct 8, 2007
Start
Sep 2001
CompletionActual
Jul 2003
Last update
Nov 28, 2007
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00540618
Lead sponsor
MedImmune LLC
First posted
Oct 8, 2007
Start date
Sep 2001
Completion
Jul 2003
Last update
Nov 28, 2007

Study contacts

Christine A Dingivan, M.D.
study director · MedImmune LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Siplizumab

Start the discussion